What are your top takeaways from ASCO GI 2026?

• GLP1 agonist use is associated with improved outcomes for colorectal cancer in a retrospective United States study. Now we need to incorporate this into randomized trials. I think this also provides more evidence that metabolic syndrome type issues may help explain early-onset colorectal cancers.
• W...

I actually haven't looked into the other disease sites, but the clear practice-changing study is the HERIZON-GEA-01 study of zanidatamab + chemo for 1L HER2 + ve EGC. These data support that zanidatamab + chemo (+/- tislelizumab) is the new SoC, replacing the prior standard of pembrolizumab/trastuzu...

In no particular order:

• HERIZON-GEA-01 continues the era of biomarker-driven care in gastroesophageal cancer (and again proves that HER2 targeting and immunotherapy are a false binary); the best comparator arm for zanidatamab + tislelizumab + chemo, though, would be against the KEYNOTE-811 quadruple...

Here are my top 3 presentations from the ASCO GI:

ILUSTRO study: This is a phase II multicohort study. At the ASCO GI 2026, the cohort 4 results were reported. This cohort evaluated zolbetuximab (a CLDN18.2-targeting monoclonal antibody) in addition to mFOLFOX6/nivolumab as first-line therapy for HE...

Targeted therapeutic approaches have again risen to the top of national/international conferences, and ASCO GI is no exception, resulting in significant benefits for patients. Importantly, these targeted approaches are increasingly investigated as initial therapy for patients with advanced disease, ...

Abstract 13: BREAKWATER: Primary analysis of first-line (1L) encorafenib + cetuximab (EC) + FOLFIRI in BRAF V600E-mutant metastatic colorectal cancer (mCRC).

This is the expected updated follow-up to the BREAKWATER data presented last year. 147 patients were randomized (EC+FOLFIRI, n=73; control (FOL...